Suppression of food intake by glucagon-like peptide-1 receptor agonists: Relative potencies and role of dipeptidyl peptidase-4

Endocrinology

Volumn 153, Issue 12, 2012, Pages 5735-5745

  Jessen, Lene ^a   Aulinger, Benedikt A ^a   Hassel, Jonathan L ^a   Roy, Kyle J ^a   Smith, Eric P ^a   Greer, Todd M ^a   Woods, Stephen C ^b   Seeley, Randy J ^a   D'Alessio, David A ^a,c  

^a Department of Internal Medicine   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANOREXIA; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; ENZYME INHIBITION; FOOD INTAKE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; ROUX Y ANASTOMOSIS;

ADAMANTANE; ANIMALS; DIPEPTIDYL PEPTIDASE 4; EATING; GENE DELETION; GENE EXPRESSION REGULATION; HETEROZYGOTE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NITRILES; PYRROLIDINES; RATS; RATS, LONG-EVANS; RECEPTORS, GLUCAGON;

EID: 84870225620     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1358     Document Type: Article

References (56)

1. Vahl TP, D'Alessio DA 2004 Gut peptides in the treatment of diabetes mellitus. Expert Opin Investig Drugs 13:177-188
2. Drucker DJ 2006 The biology of incretin hormones. Cell Metab 3:153-165
3. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ 1995 Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131
4. Lambeir AM, Durinx C, Scharpé S, De Meester I 2003 Dipeptidylpeptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40:209-294
5. Mentlein R, Gallwitz B, Schmidt WE 1993 Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835
6. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ 2011 An overview of once-weekly glucagon-like peptide-1 receptor agonists: available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 13:394-407
7. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H 2006 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49:2564-2571
8. Drucker DJ 2007 Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30:1335-1343
9. Drucker DJ, Nauck MA 2006 The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705
10. Verdich C, Flint A, Gutzwiller JP, Näslund E, Beglinger C, Hellström PM, Long SJ, Morgan LM, Holst JJ, Astrup A 2001 A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86:4382-4389
11. Barrera JG, Sandoval DA, D'Alessio DA, Seeley RJ 2011 GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol 7:507-516
12. Barrera JG, Jones KR, Herman JP, D'Alessio DA, Woods SC, Seeley RJ 2011 Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. J Neurosci 31:3904-3913
13. Merchenthaler I, Lane M, Shughrue P 1999 Distribution of pre-proglucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403:261-280
14. Shimizu I, Hirota M, Ohboshi C, Shima K 1987 Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 121:1076-1082
15. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR 1996 A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72
16. Barrera JG, D'Alessio DA, Drucker DJ, Woods SC, Seeley RJ 2009 Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes 58:2820-2827
17. Tang-Christensen M, Vrang N, Larsen PJ 2001 Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord 25(Suppl 5):S42-S47
18. Meeran K, O'Shea D, Edwards CM, Turton MD, Heath MM, Gunn I, Abusnana S, Rossi M, Small CJ, Goldstone AP, Taylor GM, Sunter D, Steere J, Choi SJ, Ghatei MA, Bloom SR 1999 Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140:244-250
19. Rodriquez de Fonseca F, Navarro M, Alvarez E, Roncero I, Chowen JA, Maestre O, Gómez R, Muñoz RM, Eng J, Blázquez E 2000 Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 49:709-717
20. Scott KA, Moran TH 2007 The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol 293:R983-R987
21. Chelikani PK, Haver AC, Reidelberger RD 2005 Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 288:R1695-R1706
22. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA, Bloom SR 2004 Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145:2687-2695
23. Baumgartner I, Pacheco-López G, Rüttimann EB, Arnold M, Asarian L, Langhans W, Geary N, Hillebrand JJ 2010 Hepatic-portal vein infusions of glucagon-like peptide-1 reduce meal size and increase c-Fos expression in the nucleus tractus solitarii, area postrema and central nucleus of the amygdala in rats. J Neuroendocrinol 22:557-563
24. 7-36inhibit food intake additively. Endocrinology 146:5120-5127
25. Williams DL, Baskin DG, Schwartz MW 2009 Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 150:1680-1687
26. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB 2007 Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 56:8-15
27. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L 2008 Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 24:2943-2952
28. Mann RJ, Nasr NE, Sinfield JK, Paci E, Donnelly D 2010 The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4. Br J Pharmacol 160:1973-1984
29. López de Maturana R, Willshaw A, Kuntzsch A, Rudolph R, Donnelly D 2003 The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1. J Biol Chem 278:10195-10200
30. Donnelly D 2012 The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br J Pharmacol 166:27-41
31. Hayes MR, Kanoski SE, Alhadeff AL, Grill HJ 2011 Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats. Obesity 19:1342-1349
32. Chambers AP, Stefater MA, Wilson-Perez HE, Jessen L, Sisley S, Ryan KK, Gaitonde S, Sorrell JE, Toure M, Berger J, D'Alessio DA, Sandoval DA, Seeley RJ, Woods SC 2011 Similar effects of rouxen-Y gastric bypass and vertical sleeve gastrectomy on glucose regulation in rats. Physiol Behav 105:120-123
33. Cummings DE 2009 Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes (Lond) 33(Suppl 1):S33-S40
34. Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G, Liu F, Woods J, Zycband E, Moller DE, Thornberry NA, Zhang BB 2003 Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 100:6825-6830
35. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N 2000 Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 97:6874-6879
36. Chambers AP, Jessen L, Ryan KK, Sisley S, Wilson-Pérez HE, Stefater MA, Gaitonde SG, Sorrell JE, Toure M, Berger J, D'Alessio DA, Woods SC, Seeley RJ, Sandoval DA 2011 Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology 141:950-958
37. Baggio LL, Drucker DJ 2007 Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157
38. Long SJ, Sutton JA, Amaee WB, Giouvanoudi A, Spyrou NM, Rogers PJ, Morgan LM 1999 No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man. Br J Nutr 81:273-279
39. Rüttimann EB, Arnold M, Geary N, Langhans W 2010 GLP-1 antagonism with exendin (9-39) fails to increase spontaneous meal size in rats. Physiol Behav 100:291-296
40. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F 2008 (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2- ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 325:175-182
41. Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, Hughes TE, Wang PR 2005 Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 315:688-695
42. Punjabi M, Arnold M, Geary N, Langhans W, Pacheco-López G 2011 Peripheral glucagon-like peptide-1 (GLP-1) and satiation. Physiol Behav 105:71-76
43. Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN, Drucker DJ, Elmquist JK 2003 Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23:2939-2946
44. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR 2011 Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 152:3103-3112
45. Holst JJ, Deacon CF 2005 Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 48:612-615
46. D'Alessio D, Lu W, Sun W, Zheng S, Yang Q, Seeley R, Woods SC, Tso P 2007 Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system. Am J Physiol Regul Integr Com Physiol 293:R2163-R2169
47. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, Ellis KS, Woods SC, Seeley RJ, Herman JP, D'Alessio DA 2007 Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148:4965-4973
48. Zhao S, Kanoski SE, Yan J, Grill HJ, Hayes MR 2012 Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner. Int J Obes (Lond) 10.1038/ijo.2011.265
49. Kastin AJ, Akerstrom V, Pan W 2002 Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 18:7-14
50. Thorens B, Porret A, Bühler L, Deng SP, Morel P, Widmann C 1993 Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42:1678-1682
51. Mann R, Nasr N, Hadden D, Sinfield J, Abidi F, Al-Sabah S, de Maturana RL, Treece-Birch J, Willshaw A, Donnelly D 2007 Peptide binding at the GLP-1 receptor. Biochem Soc Trans 35:713-716
52. Peterli R, Wölnerhanssen B, Peters T, Devaux N, Kern B, Christoffel-Courtin C, Drewe J, von Flüe M, Beglinger C 2009 Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 250:234-241
53. Korner J, Inabnet W, Febres G, Conwell IM, McMahon DJ, Salas R, Taveras C, Schrope B, Bessler M 2009 Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes 33:786-795
54. Salehi M, Prigeon RL, D'Alessio DA 2011 Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes 60:2308-2314
55. Dailey MJ, Moghadam AA, Moran TH 2011 Jejunal linoleic acid infusions require GLP-1 receptor signaling to inhibit food intake: implications for the effectiveness of Roux-en-Y gastric bypass. Am J Physiol Endocrinol Metab 301:E1184-E1190
56. Fenske WK, Bueter M, Miras a D, Ghatei M a, Bloom SR, le Roux CW 2012 Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass. Int J Obes (Lond) 36:379-384